BIOTRON LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.057 AUD | +1.79% |
|
-17.39% | -41.24% |
| 05/04 | Biotron Meets Primary Objectives of Phase Two HIV Trial; Shares Surge 25% | MT |
| 26/02 | Biotron Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Sales 2022 | 1.56M 1.02M 84.84M | Sales 2023 | 1.43M 934K 77.91M | Capitalization | 23.45M 15.31M 1.28B |
|---|---|---|---|---|---|
| Net income 2022 | -2M -1.31M -109M | Net income 2023 | -3M -1.96M -163M | EV / Sales 2022 | 26.4 x |
| Net cash position 2022 | 1.66M 1.09M 90.59M | Net cash position 2023 | 3.94M 2.57M 214M | EV / Sales 2023 | 13.6 x |
| P/E ratio 2022 |
-15.4
x | P/E ratio 2023 |
-6.11
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 80.28% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.79% | ||
| 1 week | -17.39% | ||
| Current month | -29.63% | ||
| 1 month | -25.00% | ||
| 3 months | -40.00% | ||
| 6 months | -39.36% | ||
| Current year | -41.24% |
1 week
0.06
0.07
1 month
0.060.11
Current year
0.060.12
1 year
0.020.13
3 years
0.020.13
5 years
0.020.19
10 years
0.010.45
| Managers | Title | Age | Since |
|---|---|---|---|
Michelle Miller
CEO | Chief Executive Officer | - | 21/02/21 |
Stephen Becker
CTO | Chief Tech/Sci/R&D Officer | - | 17/20/17 |
| Corporate Secretary | 67 | 23/99/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Thomas
BRD | Director/Board Member | 79 | 07/12/07 |
Michael Hoy
CHM | Chairman | 75 | 07/00/07 |
Michelle Miller
CEO | Chief Executive Officer | - | 21/02/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 0.057 | +1.79% | 498 464 |
| 29/24/29 | 0.056 | -8.20% | 3,308,478 |
| 26/24/26 | 0.061 | -10.29% | 6,837,962 |
| 24/24/24 | 0.068 | -1.45% | 828,126 |
| 23/24/23 | 0.069 | +1.47% | 328,410 |
Delayed Quote Australian S.E., April 30, 2024 at 11:40 am IST
More quotes
Biotron Limited is an Australia-based biotechnology company. The Company is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Companyâs clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.
Calendar
29/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -41.24% | 33.14M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +2.62% | 22.18B | |
| -16.67% | 21.2B | |
| -9.16% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- BIT Stock
